Usefulness of 3-month protocol biopsy of kidney allograft to detect subclinical rejection under triple immunosuppression with basiliximab: A single center experience

Clinical and Experimental Nephrology

Volumn 15, Issue 2, 2011, Pages 264-268

  Masutani, Kohsuke ^a,b   Kitada, Hidehisa ^b,c   Tsuchimoto, Akihiro ^a   Yamada, Shunsuke ^a   Noguchi, Hideko ^a   Tsuruya, Kazuhiko ^a   Tanaka, Masao ^b,c   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Banff criteria; Basiliximab; Biopsy proven acute rejection (BPAR); Calcineurin inhibitor (CNI); Mycophenolate mofetil (MMF)

Indexed keywords

BASILIXIMAB; CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG PULSE THERAPY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY BIOPSY; KIDNEY GRAFT; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOPSY; CYCLOSPORINE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 79959272340     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-010-0385-x     Document Type: Article

References (12)

1. Nankivell BJ, Chapman JR. The significance of subclinical rejection and the value of protocol biopsies. Am J Transplant. 2006;6:2006-12. (Pubitemid 44199535)
2. Roberts IS, Reddy S, Russell C, Davies DR, Friend PJ, Handa AI, et al. Subclinical rejection and borderline changes in early protocol biopsy specimens after renal transplantation. Transplantation. 2004;77:1194-8. (Pubitemid 38580296)
3. Veronese FV, Noronha IL, Manfro RC, Edelweiss MI, Goldberg J, Gonçalves LF. Prevalence and immunohistochemical findings of subclinical kidney allograft rejection and its association with graft outcome. Clin Transplant. 2004;18:357-64. (Pubitemid 39077067)
4. Miyagi M, Ishikawa Y, Mizuiri S, Aikawa A, Ohara T, Hasegawa A. Significance of subclinical rejection in early renal allograft biopsies for chronic allograft dysfunction. Clin Transplant. 2005;19:456-65. (Pubitemid 41001291)
5. Japanese Society for Clinical Renal Transplantation. Annual progress report from the Japanese renal transplant registry: Number of renal transplantation in 2008, Part 2. Jpn J Transplant. 2009;44:548-58. (Japanese).
6. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-60. (Pubitemid 351347767)
7. Duzova A, Buyan N, Bakkaloglu M, Dalgic A, Soylemezoglu O, Besbas N, et al. Triple immunosuppression with or without basiliximab in pediatric renal transplantation: acute rejection rates at one year. Transplant Proc. 2003;35:2878-80.
8. Sheashaa HA, Bakr MA, Ismail AM, Mahmoud KM, Sobh MA, Ghoneim MA. Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study. Clin Exp Nephrol. 2008;12:376-81.
9. Rush D, Nickerson P, Gough J, McKenna R, Grimm P, Cheang M, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol. 1998;9:2129-34. (Pubitemid 28482163)
10. Rush D, Arlen D, Boucher A, Busque S, Cockfield SM, Girardin C, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant. 2007;7:2538-45. (Pubitemid 47561621)
11. Takahashi K. Recent findings in ABO-incompatible kidney transplantation: classification and therapeutic strategy for acute antibody-mediated rejection due to ABO-blood-group-related antigens during the critical period preceding the establishment of accommodation. Clin Exp Nephrol. 2007;11:128-41. (Pubitemid 47012508)
12. Alarrayed SM, El-Agroudy AE, Alarrayed AS, Al Ghareeb SM, Garadah TS, El-Sharqawi SY, et al. Sirolimus-based calcineurin inhibitor withdrawal immunosuppressive regimen in kidney transplantation: a single center experience. Clin Exp Nephrol. 2010;14:248-55.